Drawing for ELLIROSE

USPTO serial 79162097

ELLIROSE

Reviewed by CopyMark Law Group

Reg. 4838987Status 706Registered
Filing date
Status date
Registration date
Oct 27, 2015
Examiner
SPRUILL, DARRYL M
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with ELLIROSE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Matthew A. Homyk

Matthew A. Homyk Blank Rome LLPOne Logan Square, 130 North 18th StreetPhiladelphia, PA 19103United States

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceutical, veterinary and sanitary products based on vegetable and plant extracts, namely, natural hibiscus flower extract; dietetic substances for medical use in the form of capsules, tablets, powders and syrups; nutritional supplements for medical use; biological preparations for medical, pharmaceutical and/or veterinary use for the treatment of urinary tract disorders; medicinal herbs; dietetic beverages adapted for medical use; ] vegetable and plant extracts for medical, pharmaceutical and/or veterinary use; vegetable and plant extracts sold as a component ingredient of nutritional supplements for medical use; [ nutritional supplements and dietetic substances in the form of capsules, tablets, powders and syrups for the prevention and treatment of urinary tract infections; ] vegetable and plant extracts used in the prevention and treatment of urinary tract infectionsACTIVE—
031Natural plants, namely, hibiscus; natural flowers, namely, hibiscusACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 17, 2026INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jul 9, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 17, 2026NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Feb 17, 202671AGREGISTERED-SEC.71 ACCEPTED—
Feb 9, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 6, 2025ES71TEAS SECTION 71 RECEIVED—
Dec 12, 2024RNWLINTERNATIONAL REGISTRATION RENEWED—
Oct 28, 2024REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Dec 25, 2022ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Oct 22, 2022NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 21, 2022NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 19, 2022NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Oct 19, 2022C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Oct 12, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Apr 26, 2022ES75TEAS SECTION 71 & 15 RECEIVED—
Oct 1, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 27, 2020REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Feb 6, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 5, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 26, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 26, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 8, 2016FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
May 19, 2016FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 19, 2016FIMPFINAL DISPOSITION PROCESSED—
Jan 27, 2016FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 27, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 21, 2015GPNXNOTIFICATION PROCESSED BY IB—
Aug 13, 2015NPUBNOTICE OF PUBLICATION—
Aug 11, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 11, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 5, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 5, 2015OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 22, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 7, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 7, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 23, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 23, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 15, 2015ALIEASSIGNED TO LIE—
Jun 8, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 24, 2015RFNTREFUSAL PROCESSED BY IB—
Apr 6, 2015RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 6, 2015RFRRREFUSAL PROCESSED BY MPU—
Apr 6, 2015RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 5, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 24, 2015MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 22, 2015DOCKASSIGNED TO EXAMINER—
Mar 20, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 19, 2015REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance